Literature DB >> 11467449

Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase.

N E Hynes1, H A Lane.   

Abstract

The proto-oncogene c-myc encodes a transcription factor which plays a major role in the regulation of normal cellular proliferation and is aberrantly expressed in many breast tumors. In a normal cell Myc expression levels are tightly regulated being subject to many layers of control. Errantly expressed Myc collaborates with other oncogenes to promote transformation. In this review we will focus on the association between abnormal Myc expression and mammary cancer. In particular, we will discuss the role of Myc as a downstream effector of the ErbB2 receptor tyrosine kinase which is overexpressed and constitutively activate in many mammary tumors. The cooperation between Myc and ErbB2 in transformation will be discussed in relation to clinical studies on Myc in human cancer and with consideration of transgenic models of Myc-induced mammary cancer. Data from our laboratory will be presented showing that deregulated ErbB2 activity strongly stimulates cytoplasmic signaling pathways which in turn impinge on Myc at multiple levels causing its deregulated expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11467449     DOI: 10.1023/a:1009528918064

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  62 in total

1.  Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay.

Authors:  I Bièche; I Laurendeau; S Tozlu; M Olivi; D Vidaud; R Lidereau; M Vidaud
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

Review 2.  Dual regulation of proliferation and apoptosis: c-myc in bitransgenic murine mammary tumor models.

Authors:  M H Jamerson; M D Johnson; R B Dickson
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

3.  c-Myc overexpression uncouples DNA replication from mitosis.

Authors:  Q Li; C V Dang
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

4.  Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

Authors:  C Escot; C Theillet; R Lidereau; F Spyratos; M H Champeme; J Gest; R Callahan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

5.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

Review 6.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

7.  Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.

Authors:  G D Lewis; J A Lofgren; A E McMurtrey; A Nuijens; B M Fendly; K D Bauer; M X Sliwkowski
Journal:  Cancer Res       Date:  1996-03-15       Impact factor: 12.701

8.  Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes.

Authors:  L M Sargent; N D Sanderson; S S Thorgeirsson
Journal:  Cancer Res       Date:  1996-05-01       Impact factor: 12.701

9.  The MYC protein activates transcription of the alpha-prothymosin gene.

Authors:  M Eilers; S Schirm; J M Bishop
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

10.  Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.

Authors:  A Scorilas; T Trangas; J Yotis; C Pateras; M Talieri
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

View more
  17 in total

1.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

2.  Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues.

Authors:  Julia Fangfei Yan; Hoguen Kim; Seul-Ki Jeong; Hyoung-Joo Lee; Manveen K Sethi; Ling Y Lee; Ronald C Beavis; Hogune Im; Michael P Snyder; Matan Hofree; Trey Ideker; Shiaw-Lin Wu; Young-Ki Paik; Susan Fanayan; William S Hancock
Journal:  J Proteome Res       Date:  2015-10-20       Impact factor: 4.466

3.  Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats.

Authors:  Jonathan J Li; S John Weroha; Wilma L Lingle; Dan Papa; Jeffrey L Salisbury; Sara Antonia Li
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-15       Impact factor: 11.205

Review 4.  Of mice and Myc: c-Myc and mammary tumorigenesis.

Authors:  M Hunter Jamerson; Michael D Johnson; Robert B Dickson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 5.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

6.  Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.

Authors:  Junling Si; Xueyan Yu; Yingjie Zhang; James W DeWille
Journal:  Mol Cancer       Date:  2010-04-28       Impact factor: 27.401

Review 7.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

8.  Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors.

Authors:  Andrea Rosner; Keiko Miyoshi; Esther Landesman-Bollag; Xin Xu; David C Seldin; Amy R Moser; Carol L MacLeod; G Shyamala; Amy E Gillgrass; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

9.  c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland.

Authors:  Tina Stoelzle; Patrick Schwarb; Andreas Trumpp; Nancy E Hynes
Journal:  BMC Biol       Date:  2009-09-28       Impact factor: 7.431

10.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer.

Authors:  Claus M Schlotter; Ulf Vogt; Ulrich Bosse; Berthold Mersch; Katja Wassmann
Journal:  Breast Cancer Res       Date:  2003-01-13       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.